Magnetic resonance imaging and ultrasound elastography in the context of preclinical pharmacological research: significance for the 3R principles

Front Pharmacol. 2023 Jun 28:14:1177421. doi: 10.3389/fphar.2023.1177421. eCollection 2023.

Abstract

The 3Rs principles-reduction, refinement, replacement-are at the core of preclinical research within drug discovery, which still relies to a great extent on the availability of models of disease in animals. Minimizing their distress, reducing their number as well as searching for means to replace them in experimental studies are constant objectives in this area. Due to its non-invasive character in vivo imaging supports these efforts by enabling repeated longitudinal assessments in each animal which serves as its own control, thereby enabling to reduce considerably the animal utilization in the experiments. The repetitive monitoring of pathology progression and the effects of therapy becomes feasible by assessment of quantitative biomarkers. Moreover, imaging has translational prospects by facilitating the comparison of studies performed in small rodents and humans. Also, learnings from the clinic may be potentially back-translated to preclinical settings and therefore contribute to refining animal investigations. By concentrating on activities around the application of magnetic resonance imaging (MRI) and ultrasound elastography to small rodent models of disease, we aim to illustrate how in vivo imaging contributes primarily to reduction and refinement in the context of pharmacological research.

Keywords: 3R principles; in vivo imaging; magnetic resonance imaging; pharmacology; preclinical research; small rodent; translational research; ultrasound elastography.

Publication types

  • Review

Grants and funding

Some of the work reported here was funded through annual research budget from Novartis Pharma AG, Basel, Switzerland. However, the company had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.